InVivoSIM anti-human CD20 (Rituximab Biosimilar)
Catalog #SIM0008
Clone:
Rituximab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Rituximab making it ideal for research use. This Rituximab biosimilar reacts with human CD20. CD20 is a B cell-specific 33-37 kDa transmembrane protein which is also known as B-lymphocyte antigen, B1, and Bp35. CD20 plays roles in intracellular calcium regulation and B cell activation and is critical for an optimal B cell immune response against T-independent antigens. CD20 is first expressed after the induction of CD19 together with IgM during the pre-B to immature B cell transition in the bone marrow. Itās expression then increases during maturation with almost all mature B cells expressing some level of CD20. However, CD20 is not expressed by plasma blasts or plasma cells. CD20 is expressed by most B cell neoplasms, and is useful in diagnosing B cell lymphomas and leukemiaās. Many anti-CD20 monoclonal antibodies are currently being used to successfully treat leukemiaās, lymphomas, and various autoimmune diseases. Rituximab has depleting activity and mediates ADCC and CDC of CD20+ cells. This results in the elimination of B cells from the body.Specifications
Isotype | Human IgG1 |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Human lymphoblastoid cell line SB |
Reported Applications |
Flow Cytometry ELISA Western Blot |
Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
Sterility | 0.2 Āµm filtration |
Production | Purified from cell culture supernatant |
Purification | Protein A |
RRID | AB_2894729 |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |